Multivariate analysis of prognostic factors and treatment arm for CIR, RFS, and OS
| Risk factor . | CIR . | RFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Genetics* | 1.56 (0.90-2.71) | .113 | 1.47 (0.81-2.69) | .208 | 1.09 (0.60-2.00) | .769 |
| Treatment† | 1.28 (0.75-2.18) | .361 | 1.70 (0.99-2.92) | .052 | 1.17 (0.68-2.02) | .570 |
| MRD‡ | 2.95 (1.48-5.90) | .002 | 3.45 (1.60-7.45) | .002 | 1.85 (0.91-3.79) | .090 |
| Risk factor . | CIR . | RFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Genetics* | 1.56 (0.90-2.71) | .113 | 1.47 (0.81-2.69) | .208 | 1.09 (0.60-2.00) | .769 |
| Treatment† | 1.28 (0.75-2.18) | .361 | 1.70 (0.99-2.92) | .052 | 1.17 (0.68-2.02) | .570 |
| MRD‡ | 2.95 (1.48-5.90) | .002 | 3.45 (1.60-7.45) | .002 | 1.85 (0.91-3.79) | .090 |
Multivariate analysis of prognostic factors and treatment arm for CIR, RFS, and OS in patients achieving complete remission with or without incomplete blood count recovery, with available genetic risk stratification and MRD assessment (N = 67), in the PETHEMA phase 3 FLUGAZA clinical trial.
Genetics: adverse vs intermediate/favorable risk.
Treatment: fludarabine and cytarabine vs azacitidine.
MRD: positive vs negative.